MYUNGMOON Pharm co.,Ltd (KRX:017180)

Market Cap	53.85B
Revenue (ttm)	188.09B
Net Income (ttm)	-3.75B
Shares Out	33.43M
EPS (ttm)	-112.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,871
Average Volume	85,451
Open	1,610.00
Previous Close	1,610.00
Day's Range	1,601.00 - 1,621.00
52-Week Range	1,412.00 - 2,740.00
Beta	0.57
RSI	43.45
Earnings Date	Aug 14, 2025

About MYUNGMOON Pharm co.,Ltd

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1983
• Employees: 282
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 017180

Financial Performance

In 2024, MYUNGMOON Pharm co.,Ltd's revenue was 186.44 billion, an increase of 9.95% compared to the previous year's 169.57 billion. Losses were -3.03 billion, -32.94% less than in 2023.